Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Peking University People's Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05467826CT.gov Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis | — | Unknown | — | — | — |
NCT02639338CT.gov Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis | — | Completed | — | — | — |
NCT02292706CT.gov A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatitis C Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Voxilaprevir (this asset) | Peking University People's Hospital | Approved | B · 63 |
| Veruprevir | AbbVie | P4 | A |
| Daclatasvir | MTI University | P4 | A |
| Glecaprevir | AbbVie | P3 | A |
| Pibrentasvir | AbbVie | P3 | A |
| Velpatasvir | Peking University People's Hospital | P4 | A |
| Ribavirin | Peking University People's Hospital | P4 | A |
| Ombitasvir | AbbVie | P3 | A |
| Sofosbuvir | Peking University People's Hospital | P4 | A |
+42 more in the Hepatitis C Virus Infection cohort
Other indications for Voxilaprevir
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cirrhosis Of Liver | — | P4 | CCC · 54 |
| Liver Cancer | — | P4 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Voxilaprevir in Hepatitis C Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/voxilaprevir-hepatitis-c-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →